Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
Organogenesis (Nasdaq: ORGO) will report second quarter fiscal 2026 financial results after market close on Thursday, August 6, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Organogenesis (Nasdaq: ORGO) will report second quarter fiscal 2026 financial results after market close on Thursday, August 6, 2026. Management will host a 5:00 p.m. ET conference call and live webcast, including a corporate update and Q&A session.
The webcast will be available at investors.organogenesis.com and archived for about one year.
Details
News Market Reaction – ORGO
On Jul 9, the day this news came out, ORGO closed 0.40% below the previous close.
Data tracked by StockTitan Argus for the Jul 9 session.
Key Figures
- Earnings period
- Second quarter fiscal 2026
- Results to be reported August 6, 2026
- Earnings release date
- August 6, 2026
- Q2 FY 2026 results after market close
- Conference call time
- 5:00 p.m. Eastern Time
- Management call on August 6, 2026
- Webcast archive duration
- Approximately one year
- Earnings call replay on company website
Previous Earnings date Reports
-
Announced Q1 2026 earnings release timing and 5:00 p.m. ET conference call.
-
Set Q4 and FY 2025 earnings release date and post-close conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that second quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, August 6th.
Management will host a conference call at 5:00 p.m. Eastern Time on August 6th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Investor Inquiries: ICR Healthcare Mike Piccinino, CFA OrganoIR@icrinc.com Press and Media Inquiries: Organogenesis communications@organo.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.